{"id":7893,"date":"2023-08-03T12:18:06","date_gmt":"2023-08-03T12:18:06","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=7893"},"modified":"2023-08-03T12:18:06","modified_gmt":"2023-08-03T12:18:06","slug":"validated-recombinant-proteins-for-ace2-covid-19-research","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/validated-recombinant-proteins-for-ace2-covid-19-research\/","title":{"rendered":"Validated Recombinant Proteins for ACE2 & COVID-19 Research"},"content":{"rendered":"\n
Product Name<\/strong><\/td>PID<\/strong><\/td>Source<\/strong><\/td>Purity<\/strong><\/td>Application\/Activity<\/strong><\/td><\/tr>
ACE2 (human) (rec.)<\/strong><\/td>AG-40B-0192<\/a><\/td>HEK293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Soluble human ACE2 competitively inhibits SARS-CoV-2 infection.<\/td><\/tr>
ACE2 (human) (rec.) (Biotin)<\/strong><\/td>AG-40B-0192B<\/a><\/td>HEK293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Soluble human ACE2 competitively inhibits SARS-CoV-2 infection.<\/td><\/tr>
ACE2 (human) (rec.) (His)<\/strong><\/td>CHI-B232008<\/a><\/td>HEK293 cells<\/td>\u226590% (SDS-PAGE)<\/td>Soluble human ACE2 competitively inhibits SARS-CoV-2 infection.<\/td><\/tr>
ACE2 (human):Fc (human) (rec.)<\/strong><\/td>CHI-B232006<\/a><\/td>HEK293 cells<\/td>\u226590% (SDS-PAGE)<\/td>Soluble human ACE2 competitively inhibits SARS-CoV-2 infection.<\/td><\/tr>
ACE2 (mouse) (rec.)<\/strong><\/td>AG-40B-0193<\/a><\/td>HEK293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Soluble mouse ACE2 negative control.<\/td><\/tr>
SARS-CoV-2 Spike Protein (D614G) (Stable Trimer) (rec.) (His)<\/strong><\/td>AG-40B-6003<\/a><\/td>HEK 293 cells<\/td>\u226590% (SDS-PAGE)<\/td>Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For structural biology research, drug and antibody screening applications and vaccine development.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His)<\/strong><\/td>AG-40B-0195<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (Biotin)<\/strong><\/td>AG-40B-0195B<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>This protein forms a tetramer in the presence of streptavidin and this tetramer can be used to activate B cell memory to SARS-CoV-2 Spike protein.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His)<\/strong><\/td>CHI-B232004<\/td>HEK 293 cells<\/td>\u226590% (SDS-PAGE)<\/td>Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (B.1.1.7 Variant, Alpha)<\/strong><\/td>AG-40B-0205<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (B.1.351 Variant, Beta)<\/strong><\/td>AG-40B-0206<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (P.1 Variant, Gamma)<\/strong><\/td>AG-40B-0207<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (B.1.617.1 Variant, Kappa)<\/strong><\/td>AG-40B-0208<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (GST-His)<\/strong><\/td>CHI-B249001<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.)\u00a0<\/strong><\/td>CHI-B232003<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.)<\/strong><\/td>AG-40B-0194<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.1.7 Variant, Alpha)<\/strong><\/td>AG-40B-0202<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>More transmissible variant of SARS-CoV-2, called B.1.1.7 that carries a mutation in the RBD at the position 501 (N501Y).For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.351 Variant, Beta)<\/strong><\/td>AG-40B-0203<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>New variant of SARS-CoV-2, called B.1.351, that carries three mutations in the RBD at the positions 417, 484 and 501 (K417N, E484K, N501Y) and is associated with a higher viral load with potential for increased transmissibility. For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (P.1 Variant, Gamma)<\/strong><\/td>AG-40B-0204<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>New variant of SARS-CoV-2, called P.1 that carries three mutations in the RBD at the positions 417, 484 and 501 (K417T, E484K, N501Y). For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.617.1 Variant, Kappa)<\/strong><\/td>AG-40B-0209<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>New variant of SARS-CoV-2, called B.1.617.1 that carries two mutations in the RBD at the positions 452 and 484 (L452R, E484Q). For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.617.2 Variant, Delta)<\/strong><\/td>AG-40B-0211<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>New variant of SARS-CoV-2, called B.1.617.2 that carries two mutations in the RBD at the positions 452 and 478 (L452R, T478K). For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.617.2.1 Variant, Delta Plus)<\/strong><\/td>AG-40B-0212<\/a><\/td>HEK 293 cells<\/td>\u226595% (SDS-PAGE)<\/td>New variant of SARS-CoV-2, called B.1.617.2.1 that carries three mutations in the RBD at the positions 417, 452 and 478 (K417N, L452R, T478K). For drug and antibody screening applications and immunization.<\/td><\/tr>
SARS-CoV-2 Nucleocapsid Protein (rec.) (His)<\/strong><\/td>CHI-B233501<\/a><\/td>E. coli<\/td>\u226595% (SDS-PAGE)<\/td>For drug screening applications.<\/td><\/tr>
PLpro (SARS Coronavirus) (rec.) (His)<\/strong><\/td>SBB-DE0024<\/a><\/td>E. coli<\/td>\u226595% (SDS-PAGE)<\/td>Involved in the processing of the viral polyprotein.<\/td><\/tr>
ISG15 (human) (rec.) (Rhodamine 110)<\/strong><\/td>SBB-PS0002<\/a><\/td>E. coli<\/td>\u226597% (LCMS)<\/td>PLPro substrate. Inhibits viral budding and acts as IFN\u03b3-inducing cytokine.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Originally posted on adipogen.com\/covid-19<\/a><\/p>\n\n\n\n

Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

List of AdipoGen Life Sciences’ validated recombinant proteins for ACE2 & COVID-19 research<\/p>\n","protected":false},"author":13,"featured_media":7886,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[517,641],"tags":[524,279,515,58],"class_list":["post-7893","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19","category-recombinant-proteins","tag-ace2","tag-adipogen","tag-covid-19","tag-recombinant-proteins"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/7893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=7893"}],"version-history":[{"count":1,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/7893\/revisions"}],"predecessor-version":[{"id":7894,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/7893\/revisions\/7894"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/7886"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=7893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=7893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=7893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}